NCT00762190View on ClinicalTrials.gov

Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

PHASE3TerminatedINTERVENTIONAL
Enrollment

348

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions
Diabetes Mellitus
Interventions
DRUG

TAK-559 and insulin

TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.

DRUG

Insulin

TAK-559 placebo-matching, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY